On reopening during #COVID19: “To me it seems like there’s a much higher risk when we’re considering something like… https://t.co/Z5wpvvaSKm
A new normal—less limiting than stay-home orders, but far different from what we're used to—lies ahead in the wake… https://t.co/HSYpSNW2TU
Online now in @JAMAInternalMed: a new study on OOP #insulin costs, led by @DeptPopMed / @HealthPolicyDPM’s… https://t.co/S2QZ58S0xN
Research Fellow Amir Meiri's research examines the implications of drug pricing on health outcomes among the diabetes populations, specifically focused on better understanding the impact of insurance benefit design on insulin costs and pricing among a population with diabetes. His most recent study in JAMA Internal Medicine examined insulin out-of-pocket costs and reimbursement price from 2006-2017 among patients with commercial insurance. We spoke with Dr. Meiri to learn more about the study, what the team learned, and what direction his future research might take.
Welcome to our spotlight series, where we look beyond the CV and learn more about our investigators. Meet Kurt Christensen, who joined our department as a faculty member in late 2019. Dr. Christensen’s research focuses on the medical, behavioral, and economic impact of integrating genomic tools into clinical and research settings.